STM JOURNALS

Research & Reviews: A Journal of
Medicine

ISSN: 2249-8648 (Online)
ISSN: 2348-7917 (Print)
Volume 14, Issue 1, 2024
DOI (Journal): 10.37591/RRJoM

http://medicaljournals.stmjournals.in/index.php/RRJoM/index

Research RRJoM

Unraveling Ulcerogenesis: A Comprehensive Delve of Enteric & Nonenteric Ulcers

Rishav Brijpuriya[1], Neelam Balekar[2,*], Ayushi Rai[3]

Abstract

Enteric ulcers present a multifaceted landscape encompassing both peptic and non-peptic varieties, demanding a thorough exploration of their manifestations, causes, and pathophysiology. At the forefront of understanding lie pivotal factors such as Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs usage, lifestyle choices, and stress, each wielding significant influence over ulcer development and progression. The intricate interplay of these factors underscores the complexity of enteric ulcer etiology. Helicobacter pylori infection—a prevalent culprit—inflicts chronic gastritis and mucosal damage, fostering an environment ripe for ulcer formation. Stress, recognized as a potent modulator of gastrointestinal function, amplifies susceptibility to ulceration via mechanisms involving altered gastric acid secretion and mucosal blood flow. Diagnosis of enteric ulcers demands astute clinical acumen and judicious employment of diagnostic modalities such as endoscopy, biopsy, and non-invasive testing for Helicobacter pylori. Prompt identification and treatment are paramount, emphasizing the critical role of healthcare professionals in orchestrating tailored intervention plans. Treatment strategies encompass a multifaceted approach targeting causative factors and symptom relief. Helicobacter pylori eradication regimens, coupled with acid-suppressing medications and cytoprotective agents, form the cornerstone of pharmacotherapy. Lifestyle modifications, including dietary adjustments and stress management techniques, complement pharmacological interventions to optimize therapeutic outcomes. A holistic understanding of enteric ulcers empowers healthcare professionals to navigate the intricacies of diagnosis and treatment, thereby fostering positive outcomes and enhancing the quality of life for individuals grappling with this debilitating condition. By embracing a comprehensive paradigm encompassing etiology, diagnosis, and management, clinicians stand poised to alleviate suffering and promote wellness in patients afflicted with enteric ulcers.

***Author for Correspondence**
Neelam Balekar
E-mail: neelambalekar@ipsacademy.org

[1]Student, Department of Pharmacology, IPS Academy College of Pharmacy, Indore, Madhya Pradesh, India
[2]Professor, Department of Pharmacology, IPS Academy College of Pharmacy, Indore, Madhya Pradesh, India
[3]Assistant Professor, Department of Pharmacology, IPS Academy College of Pharmacy, Indore, Madhya Pradesh, India

Received Date: January 29, 2024
Accepted Date: February 02, 2024
Published Date: April 18, 2024

Citation: Brijpuriya R, Balekar N, Rai A. Unraveling Ulcerogenesis: A Comprehensive Delve of Enteric & Non-enteric Ulcers. Research & Reviews: A Journal of Medicine. 2024; 14(1): 25–37p.

Keywords: ulcers, gastroesophageal reflux disease, inflammatory bowel diseases, nonsteroidal anti-inflammatory drugs, *Helicobacter pylori*

INTRODUCTION

Ulcers manifest as open sores on the digestive tract lining, frequently found in the stomach or small intestine. They can be recognized by an uncomfortable burning sensation and result from an upset in the

balance between stomach acid and the protective layer of mucus. Contributing factors encompass bacterial infection (such as *Helicobacter pylori*), prolonged nonsteroidal anti-inflammatory drugs (NSAIDs) usage, and stress. Manifestations span from abdominal discomfort to nausea. Addressing ulcers entails using medications to diminish acid production and facilitate healing. Neglected ulcers can result in complications, underscoring the significance of prompt medical attention [1, 2].

TYPES OF ENTERIC ULCERS

Enteric ulcers denote a collection of sores impacting the mucous linings of the gastrointestinal (GI) tract. These ulcers can be broadly categorized into peptic and nonpeptic ulcers, each with distinct subtypes. Understanding the types of enteric ulcers is crucial for proper diagnosis and treatment as shown in Figure 1 [2].



Figure 1. Various types of ulcers.

Peptic Ulcers

Gastric Ulcers

Gastric ulcers are a common type of peptic ulcers that emerge within the lining of the stomach. The stomach, with its potent gastric juices, is a hostile environment for most microbes, but sometimes, this harsh environment can lead to the breakdown of the protective mucosal layer. Causes such as *H. pylori* bacterial infection, prolonged usage of NSAIDs, and

increased acid production can contribute to the formation of gastric ulcers. Patients with gastric ulcers may experience symptoms such as abdominal pain, bloating, and nausea [3].

Duodenal Ulcers

Duodenal ulcers appear in the upper part of the small intestine, known as the duodenum. Similar to gastric ulcers, they are frequently linked to *H. pylori* infection and the use of NSAIDs. The duodenum is exposed to gastric acid after food leaves the stomach, making it susceptible to ulceration. Duodenal ulcers may present with pain, often described as a burning sensation, and can be aggravated or alleviated by eating [4].

Nonpeptic Ulcers

Esophageal Ulcers

Esophageal ulcers, located in the muscular tube connecting the throat to the stomach, often stem from Gastroesophageal Reflux Disease (GERD). In GERD, stomach acid flows back into the esophagus, causing irritation and potentially resulting in the formation of ulcers. Apart from GERD, factors such as infections, specific medications, and systemic diseases can also play a role in the formation of esophageal ulcers. Common symptoms include pain or challenges while swallowing, heartburn, and regurgitation [5].

Colonic Ulcers

Ulcers occurring in the colon, which is responsible for absorbing water and electrolytes from undigested food, can be linked to inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. The persistent inflammation associated with IBD results in ulcer formation, which can lead to symptoms such as abdominal pain, diarrhoea, and weight loss. Understanding the differences between these types of enteric ulcers is essential for accurate diagnosis and effective management. Peptic ulcers, specifically those affecting the stomach and duodenum, frequently have overlapping risk factors and exhibit similar symptoms. Non-peptic ulcers, such as esophageal and colonic ulcers, have distinct causes and manifestations that necessitate a tailored approach to treatment [6].

In summary, enteric ulcers encompass a diverse group of lesions affecting different parts of the digestive tract. Peptic ulcers, encompassing both gastric and duodenal ulcers, frequently correlate with conditions such as *H. pylori* infection and the consumption of NSAIDs. Nonpeptic ulcers, such as esophageal and colonic ulcers, have unique etiologies, with GERD and IBD being significant contributors. Recognizing the specific type of enteric ulcer is crucial for healthcare professionals to implement appropriate treatment strategies and provide relief to patients experiencing the often-debilitating symptoms associated with these conditions [7].

CAUSES OF ENTERIC ULCERS

Enteric ulcers, both peptic and nonpeptic, can be attributed to a variety of causes, ranging from microbial infections to lifestyle factors. Recognizing these fundamental reasons is crucial for preventing, promptly identifying, and efficiently managing ulcer-related issues [8] (Figure 2).

Helicobacter pylori

A leading factor in the occurrence of peptic ulcers is *H. pylori*—a bacterial infection impacting the stomach lining. This spiral-shaped bacterium has the capacity to compromise the

protective mucous layer of the stomach, rendering it more vulnerable to the harmful impacts of gastric acid.

H. pylori is recognized as a significant contributor to the formation of both gastric and duodenal ulcers. Typically acquired during childhood, this infection can endure for an extended period unless treated with suitable antibiotics [9].



Figure 2. Causes of enteric ulcers.

NSAIDs

The heightened risk of developing ulcers is linked to the extended usage of NSAIDs such as aspirin and ibuprofen. These drugs suppress the synthesis of prostaglandins, which are compounds that aid in shielding the stomach lining against the harmful impacts of gastric acid. By reducing prostaglandin levels, NSAIDs can compromise the stomach's natural defence mechanisms, leading to the development of peptic ulcers. Individuals who rely on NSAIDs for chronic pain management are particularly susceptible to this risk [9].

Smoking and Alcohol

Habits such as smoking and excessive alcohol intake have been recognized as factors that contribute to the development of ulcers. Smoking can interfere with the protective mechanisms of the GI tract, impairing blood flow and increasing susceptibility to ulcers. Alcohol, on the other hand, can irritate the stomach lining and enhance gastric acid production, creating an environment conducive to ulcer formation. Combining smoking and alcohol further elevates the risk [10].

Stress

Although stress does not directly cause ulcers, it can worsen pre-existing conditions and contribute to their ongoing presence. Stress may impact the body's ability to heal and repair damaged mucosal tissue in the digestive tract. Additionally, stressful situations can stimulate the production of stomach acid, potentially worsening symptoms for individuals with peptic ulcers. Effective stress management is crucial for individuals with ulcerative conditions to promote healing and prevent recurrence [11, 12].

PATHOPHYSIOLOGY OF ENTERIC ULCERS

Enteric ulcers, including both peptic and nonpeptic types, share a common pathophysiology characterized by a disruption of the mucosal barrier, alterations in acid production, and

inflammation. It is essential to grasp the fundamental pathophysiological mechanisms to formulate successful treatment approaches and interventions [13].

Mucosal Barrier Disruption

The mucosal barrier plays a critical role in protecting the lining of the digestive tract from the harsh conditions within the stomach and intestines. This barrier is composed of a layer of mucus, bicarbonate, and various protective substances that shield the mucosa from the corrosive effects of gastric acid. In the context of enteric ulcers, this protective mechanism is compromised. Factors such as *H. pylori* infection and prolonged use of NSAIDs can disrupt the integrity of the mucosal barrier, making the underlying tissue more vulnerable to damage [11, 13].

Acid Production

The balance between acid production and mucosal defence mechanisms is crucial for maintaining the health of the GI tract. In individuals with enteric ulcers, there is an imbalance in this delicate equilibrium. High levels of acid production or a decline in the efficiency of mucosal defence mechanisms can foster an environment suitable for the development of ulcers. In the case of peptic ulcers, the acidic contents of stomach can penetrate the compromised mucosal barrier, leading to erosion of the underlying tissue. This acid-induced damage contributes to the characteristic symptoms associated with enteric ulcers, such as pain and discomfort [14].

Inflammation

Inflammatory mechanisms significantly contribute to the pathophysiology of enteric ulcers. Chronic inflammation is a common feature, particularly in conditions such as IBD that can lead to colonic ulcers. In the context of peptic ulcers, inflammation is often triggered by factors such as *H. pylori* infection. Inflammation not only contributes to the erosion of the mucosal barrier but also perpetuates a cycle of tissue damage and repair. The presence of inflammatory cells and mediators further exacerbates the symptoms and complications associated with enteric ulcers [14].

SYMPTOMS OF ENTERIC ULCERS

The symptoms of enteric ulcers can vary in severity and presentation, but they often share common manifestations that reflect the underlying damage to the GI mucosa. Identifying these symptoms is essential for swift diagnosis and proper treatment [7]. The symptoms associated with enteric ulcers are given in Figure 3.



Figure 3. Symptoms of enteric ulcers.

Pain

The hallmark symptom of enteric ulcers is abdominal pain, typically described as a burning sensation. The discomfort is typically centered in the upper abdomen and might occur between meals or at night, particularly when the stomach is empty. The intensity and duration of the pain can fluctuate, and its response to eating can either alleviate or worsen depending on the type and site of the ulcer [15].

Indigestion

Individuals with enteric ulcers may experience indigestion, characterized by a feeling of bloating and discomfort after eating. The impaired mucosal barrier and increased acid production contribute to digestive disturbances, leading to symptoms such as belching, bloating, and a sense of fullness even with small meals [15].

Nausea and Vomiting

Nausea is a common symptom in individuals with enteric ulcers, and in more severe cases, it can progress to vomiting. Vomiting may occur due to the irritation of the stomach lining and the body's response to the presence of ulcers. Persistent nausea and vomiting may lead to dehydration and electrolyte imbalances, requiring medical attention [15].

Bleeding

Ulcers in the intestines can result in bleeding, which may present in various forms. Melena, characterized by black, tarry stools, occurs when blood from the ulcer mixes with the stool. Hematemesis, or vomiting blood, is another serious complication of enteric ulcers. Bleeding can result from the erosion of blood vessels within the ulcerated tissue and can lead to anaemia if left untreated. It is important to recognize that the intensity and assortment of symptoms can differ from person to person, and certain individuals with enteric ulcers may not display any symptoms. Nevertheless, if symptoms persist or become severe, seeking medical assessment is crucial to identify the root cause and commence suitable treatment.

In conclusion, the symptoms of enteric ulcers, including pain, indigestion, nausea, vomiting, and bleeding, reflect the impact of mucosal damage and inflammation on the GI tract. Identifying these symptoms is vital for early diagnosis and intervention, enabling healthcare providers to customize treatment strategies according to the unique requirements of individuals with enteric ulcers and to avert complications such as bleeding and perforation [15].

DIAGNOSIS OF ENTERIC ULCERS

The diagnosis of enteric ulcers involves a combination of clinical evaluation and diagnostic procedures to identify the presence of ulcers, determine their location, and assess potential underlying causes. The key diagnostic methods commonly employed in the identification of enteric ulcers are described in the later sections [16].

Endoscopy

Endoscopy is a primary diagnostic tool for enteric ulcers, allowing for direct visualization of the GI tract. During an upper endoscopy, a flexible tube containing a light and camera, referred to as an endoscope, is inserted through the mouth and guided into the esophagus, stomach, and duodenum. This procedure enables the healthcare provider to observe the ulcer directly, assess its size and location, and sometimes obtain tissue samples for biopsy [16, 17].

Biopsy

Biopsy involves the collection of small tissue samples from the ulcerated area during an endoscopy. Subsequent to obtaining tissue samples, they are scrutinized under a microscope to ascertain the presence of *H. pylori* bacteria. *H. pylori* infection is a prevalent factor in the development of peptic ulcers, and detecting its existence can inform the implementation of suitable treatment approaches. Biopsy results also help rule out other potential causes of ulcers, such as malignancies [17].

Barium X-Ray

A barium X-ray, referred to as an upper GI series, is a radiographic technique where a patient ingests a barium contrast solution. The barium solution adheres to the interior lining of the digestive tract, rendering it detectable on X-ray images. This diagnostic method is particularly useful for detecting ulcers in the stomach and duodenum. Barium X-ray can reveal the size, shape, and location of ulcers, providing valuable information for diagnosis [17].

Blood Tests

Blood tests might be performed to examine particular indicators linked with *H. pylori* infection, like antibodies or antigens. Additionally, blood tests can assess for anaemia, which may result from chronic bleeding associated with bleeding ulcers [12, 17].

Stool Tests

Stool examinations can be conducted to identify the existence of *H. pylori* antigens in faecal samples. This non-invasive approach serves as an alternative to biopsy for detecting *H. pylori* infection [17].

Imaging Studies

In specific instances, supplementary imaging examinations, such as computed tomography (CT) scans or magnetic resonance imaging (MRI), might be utilized to assess the severity of complications or exclude alternative medical conditions. Utilizing a combination of these

diagnostic approaches enables healthcare providers to precisely diagnose enteric ulcers, detect *H. pylori* infection, and eliminate other potential causes. A comprehensive diagnostic approach is crucial for tailoring effective treatment plans and managing enteric ulcers based on the specific characteristics of each individual case [12].

TREATMENT OF ENTERIC ULCERS

Treating enteric ulcers requires a comprehensive strategy that targets the root causes, alleviates symptoms, supports healing, and reduces the risk of recurrence [18]. The key components of the treatment for enteric ulcers include:

H. pylori Eradication

For ulcers associated with *H. pylori* infection, the primary approach is to eradicate the bacteria [19]. This is commonly accomplished using a blend of antibiotics and proton pump inhibitors (PPIs). Antibiotics such as clarithromycin, amoxicillin, and metronidazole might be recommended to specifically target and eradicate the *H. pylori* bacteria. PPIs, such as omeprazole, lansoprazole, or esomeprazole, are used to reduce stomach acid production, creating an environment less conducive to ulcer formation and allowing the antibiotics to be more effective [20].

Acid-Suppressing Medications

Acid-suppressing medications play a crucial role in the treatment of enteric ulcers, regardless of whether *H. pylori* is present. PPIs and H2 blockers are commonly recommended to reduce the production of gastric acid. PPIs, as mentioned earlier, inhibit the proton pump responsible for acid secretion, while H2 blockers, such as ranitidine or famotidine, target histamine receptors in the stomach lining to decrease acid production. These medications help alleviate symptoms, promote healing of the ulcerated tissue, and prevent recurrence [21].

Cytoprotective Agents

Cytoprotective agents aim to enhance the mucosal defence mechanisms, promoting the healing of the damaged GI lining. Sucralfate exemplifies a cytoprotective agent that creates a protective barrier around the ulcer, guarding it against the harmful effects of stomach acid. This promotes healing and reduces symptoms [19].

Lifestyle Modifications

Lifestyle changes are often recommended to complement medical treatment. These may include avoiding or limiting the use of NSAIDs, quitting smoking, moderating alcohol consumption, and adopting a diet that minimizes irritants to the GI tract [20].

Symptomatic Relief

Medications such as antacids may be used for symptomatic relief to neutralize stomach acid and alleviate pain. Additionally, anti-nausea medications may be prescribed for individuals experiencing nausea and vomiting [21].

Follow-up Endoscopy

Occasionally, a subsequent endoscopic examination may be conducted to evaluate the ulcer's healing progress and verify the effective eradication of *H. pylori*. Treatment selection relies on the distinct features of the ulcer, the existence of *H. pylori* infection, and individual patient considerations. Individuals with enteric ulcers should adhere to the recommended treatment

regimen, attend follow-up sessions, and keep an open line of communication with healthcare providers about any lingering or worsening symptoms [8, 20, 21].

Kangfuxin

The efficacy of Kangfuxin (KFX) treatment in addressing gastric ulcers is effective. Noteworthy was its ability to provide gastroprotective effects, primarily attributed to the substantial promotion of neovascularization, suppression of inflammation, and heightened expression of diverse growth factors. The activation of p38/NF-κB pathway emerged as a significant mechanism through which KFX exerts its effects. This suggests that KFX holds promise as a therapeutic agent for gastric ulcer treatment. Furthermore, combining KFX with conventional drugs in treatment regimens showed positive outcomes, indicating the potential for synergistic effects in enhancing the overall efficacy of gastric ulcer treatments. Overall, the findings of the present study underscored the multifaceted benefits of KFX, positioning it as a valuable candidate for further exploration and development in the realm of gastric ulcer therapeutics [1].

PREVENTION OF ENTERIC ULCERS

Preventing enteric ulcers involves adopting lifestyle changes and practicing measures to reduce the risk factors associated with ulcer development [22]. The key strategies for preventing enteric ulcers are given below:

Lifestyle Changes

Quit Smoking

Smoking poses a substantial risk for the onset of enteric ulcers. Ceasing smoking not only lowers the chances of developing ulcers but also offers various other health advantages [22].

Limit Alcohol Consumption

Consuming too much alcohol can inflame the lining of the stomach and elevate the likelihood of developing ulcers. Moderating alcohol consumption is advisable for overall GI health [22].

Avoid NSAIDs

NSAIDs, including aspirin and ibuprofen, may play a role in the formation of enteric ulcers. If these medications are required, it is recommended to use them with the supervision of a healthcare provider, and other methods of pain management can be considered [23].

H. pylori Prevention

Safe Food Practices

Adhering to safe food handling and hygiene practices can aid in the prevention of *H. pylori* infection—a prevalent contributor to peptic ulcers. This involves washing fruits and vegetables thoroughly, ensuring meats are cooked to a safe temperature, and refraining from eating undercooked or contaminated food [4, 19].

Good Personal Hygiene

H. pylori is primarily transmitted through person-to-person contact. Practicing good personal hygiene, such as frequent handwashing, can help reduce the risk of infection [4].

Stress Management

Chronic stress is not a direct cause of enteric ulcers, but it can exacerbate existing conditions. Stress management techniques, such as mindfulness, relaxation exercises, and regular physical activity, can contribute to overall well-being and potentially reduce the impact of stress on the GI system [16].

Medication Management

If NSAIDs are prescribed for chronic conditions, healthcare providers may consider co-prescribing medications to protect the stomach lining, such as PPIs or prostaglandin analogs [11].

Regular Health Check-Ups

Routine health examinations and screenings can assist in recognizing risk factors and conditions that might contribute to enteric ulcers. People who have had ulcers or other GI problems in the past should engage with their healthcare providers to devise preventative plans [16, 11].

Early Intervention

Addressing symptoms promptly and seeking medical attention for persistent abdominal pain, indigestion, or other GI symptoms can contribute to early detection and intervention, preventing the progression of ulcers to more severe complications.

In summary, prevention of enteric ulcers involves a combination of lifestyle modifications, hygiene practices, and proactive healthcare management. Adopting a healthy lifestyle, avoiding risk factors, and seeking timely medical attention can contribute to reducing the incidence of enteric ulcers and promoting overall GI health. People with particular risk factors or concerns should seek advice from healthcare professionals for personalized guidance and preventive strategies [7].

PROGNOSIS FOR ENTERIC ULCER PATIENTS

The prognosis for individuals with enteric ulcers is generally favourable, especially with appropriate and timely medical intervention. The key factors related to the prognosis of enteric ulcers are described as follows:

Healing Time

Enteric ulcers, when diagnosed and treated promptly, often respond well to medical intervention. The duration for healing can differ based on factors such as the size and location of ulcer, the presence of *H. pylori* infection, and individuals' response to the treatment. With the use of medications such as PPIs, antibiotics, and other supportive measures, the majority of ulcers can heal within weeks to months [24].

Recurrence

Enteric ulcers tend to recur, especially if underlying risk factors persist or if the initial treatment plan is not followed. Hence, continuous management and follow-up care are essential to avoid recurrence. Monitoring for the recurrence of symptoms and regular check-ups with healthcare providers can help detect and address any emerging issues before they progress to more severe complications [24].

Complication Prevention

Timely and effective treatment not only promotes ulcer healing but also helps prevent complications such as perforation, bleeding, or obstruction. Adequate management of *H. pylori* infection, if present, is particularly important in preventing recurrence and complications [24].

Lifestyle Modifications

Individuals who make sustained lifestyle changes, such as quitting smoking, moderating alcohol consumption, and avoiding the use of NSAIDs, can contribute to a positive prognosis by reducing the risk factors associated with enteric ulcers [25].

Adherence to Medications

Adherence to prescribed medications, including acid-suppressing medications and antibiotics for *H. pylori* eradication, is crucial for successful treatment and prevention of recurrence. Skipping doses or prematurely discontinuing medications may compromise the healing process and increase the likelihood of recurrence [25].

Individual Factors

Different personal elements such as overall health, the presence of underlying medical conditions, and genetic predispositions can affect the outlook. It is crucial for healthcare providers to consider these factors when tailoring treatment plans and providing prognostic advice to patients [25].

BIOMARKERS

Biomarkers are indispensable tools in diagnosing and understanding both peptic and nonpeptic (stress) ulcers, shedding light on various aspects of these GI conditions. A thorough exploration of the significance of each biomarker enhances our understanding [26].

Biomarkers for Peptic Ulcers

H. pylori Antibodies

H. pylori antibodies are pivotal for diagnosing *H. pylori* infections associated with peptic ulcers. Positive results prompt further investigation, guiding treatment strategies to address potential ulceration [26].

Serum Gastrin Levels

Elevated serum gastrin levels indicate an imbalance in gastric acid regulation, contributing to peptic ulcer development. Monitoring aids in identifying at-risk individuals and implementing targeted interventions [27].

Serum Pepsinogen

Serum pepsinogen is vital for evaluating gastric health, signalling disruptions linked to peptic ulcer development. Deviant levels act as a warning sign, facilitating timely intervention and focused management [27].

Faecal Occult Blood Test (FOBT)

Faecal occult blood test **(**FOBT) is crucial for identifying GI bleeding—a common symptom of peptic ulcers. Positive results prompt further investigation, facilitating timely identification and assessment of ulcer-related complications [28].

Endoscopic Findings

Endoscopy is the gold standard for diagnosing ulcers, providing detailed information for targeted treatment plans. It is indispensable in the comprehensive evaluation of GI health [29].

Biomarkers For Nonpeptic (Stress) Ulcers

Cortisol Levels

Cortisol levels reflect heightened stress, especially in critically ill patients. Monitoring serves as a critical indicator, prompting measures to minimize stress ulcer risk [30].

Serum Amylase and Lipase

Elevated levels indicate physiological stress and potential pancreatic involvement in stress ulcer development. Monitoring aids in formulating comprehensive treatment strategies [31].

Serum C-Reactive Protein

Elevated C-reactive protein (CRP) levels indicate an inflammatory response triggered by stress, contributing to ulcer pathophysiology. Monitoring aids in assessing the physiological impact of stress on the GI system [31].

Platelet Count

Thrombocytopenia serves as a valuable marker of severe stress and critical illness, correlating with an increased risk of stress ulcerative complications [31].

Endoscopic Findings

Endoscopy remains critical for diagnosing stress ulcers, aiding in the identification and characterization of stress-induced lesions. Visualizing these lesions contributes to targeted treatment strategies for stress-related GI complications [32].

In summary, biomarkers are pivotal in diagnosing and understanding peptic and stress ulcers, providing valuable insights for targeted treatment strategies and improved patient outcomes.

FUTURE SCOPE

The future of enteric ulcer management is likely to see continued advancements in diagnostics, treatment modalities, and preventive strategies [33]. Some potential directions for the future of enteric ulcer care are given below:

Precision Medicine

Progress in comprehending the genetic and molecular elements involved in enteric ulcers could result in treatment methods tailored to individual needs. Customizing interventions according to an individual's genetic composition and distinct risk factors could enhance treatment results [33, 34].

Innovative Therapies

Ongoing research may uncover novel therapeutic targets and medications for enteric ulcers. New drugs that address mucosal healing, inflammation, and microbial infections with greater efficacy and fewer side effects could enhance treatment options [35].

Microbiome Research

Further exploration of the gut microbiome's role in GI health may provide insights into preventing and treating enteric ulcers. Probiotics, prebiotics, and faecal microbiota transplantation could emerge as potential therapies to restore and maintain a healthy gut environment [36].

Advanced Imaging Techniques

Advancements in imaging technologies may offer more detailed and accurate assessments of ulcer characteristics, allowing for better localization, sizing, and monitoring of ulcers. This could aid in treatment planning and assessing the effectiveness of interventions [36].

Telemedicine and Digital Health

Incorporating telemedicine and digital health technologies could improve post-treatment support, patient education, and symptom monitoring. Remote monitoring and virtual consultations could improve patient engagement and accessibility to healthcare services [8].

Artificial Intelligence in Diagnostics

Application of artificial intelligence (AI) may play a role in improving the accuracy and efficiency of diagnosing enteric ulcers. AI algorithms examining endoscopic images, biopsy findings, and patient information could aid healthcare providers in delivering more accurate and prompt diagnoses [36].

Patient-Centered Care

Increasing emphasis on patient-centered care may involve empowering individuals with enteric ulcers to actively participate in their treatment plans. Education, support networks, and tools for self-management could become integral components of future care strategies [36].

Lifestyle and Behavioral Interventions

Research into the impact of lifestyle and behavioral interventions on enteric ulcers may lead to more comprehensive approaches to prevention and management. Strategies focusing on stress reduction, dietary modifications, and holistic well-being could complement medical treatments [36].

Long-Term Monitoring

Long-term monitoring strategies may evolve to include non-invasive methods for assessing ulcer healing and detecting potential complications. Biomarkers, wearable devices, and home-based monitoring tools could contribute to more proactive and continuous care [33, 36].

As healthcare evolves, collaboration across disciplines, continual research, and technological advancements are expected to influence the future of managing enteric ulcers. The integration of these developments into clinical practice holds the potential to further improve outcomes, reduce complications, and enhance the overall quality of life for individuals affected by enteric ulcers. Enteric ulcers are a significant health concern, often attributed to factors such as *H. pylori* infection, NSAIDs use, and lifestyle choices. Early detection and proper treatment can result in successful recovery and help prevent complications. A healthy lifestyle and risk factor management are vital for prevention of enteric ulcers. Regular medical check-ups are crucial for successful monitoring and management of enteric ulcers [37].

CONCLUSION

Enteric ulcers, comprising both peptic and nonpeptic variants, present significant digestive health challenges but can be effectively addressed through prompt diagnosis and targeted interventions. A nuanced comprehension of the diverse types, causes, and pathophysiology of enteric ulcers is essential for healthcare professionals to tailor treatment plans. Early recognition of symptoms, precise diagnostic methods, and a multifaceted treatment approach,

including antibiotics, acid suppression, and lifestyle adjustments, contribute to positive outcomes. Proactive management, coupled with lifestyle changes and ongoing research, continues to refine our approach to enhance the overall quality of life for those affected by enteric ulcers.

Financial Support and Sponsorship
Nil.

Conflicts of Interest
There are no conflicts of interest.

REFERENCES

1. Tian M, Dong J, Wang Z, Lu S, Geng F. The effects and mechanism of Kangfuxin on improving healing quality and preventing recurrence of gastric ulcer. Biomedicine & Pharmacotherapy. 2021; 138: 111513.
2. Mustafa M, Menon J, Muiandy RK, Fredie R, Sein MM, Fariz A. Risk factors, diagnosis, and management of peptic ulcer disease. J Dent Med Sci. 2015; 14(7): 40–46p.
3. Shim YK, Kim N. Nonsteroidal anti-inflammatory drug and aspirin-induced peptic ulcer disease. The Korean Journal of Gastroenterology. 2016; 67(6): 300–312p.
4. Tsongo L, Nakavuma J, Mugasa C, Kamalha E. Helicobacter pylori among patients with symptoms of gastroduodenal ulcer disease in rural Uganda. Infection Ecology & Epidemiology. 2015; 5(1): 26785.
5. Yuan Y, Padol IT, Hunt RH. Peptic ulcer disease today. Nature Clinical Practice Gastroenterology & Hepatology. 2006; 3(2): 80–89p.
6. Ammar AS, Khalid AU, Noumani AR. A case report of duodenal and enteric perforation in a single patient. European Journal of Medical Case Reports. 2020; 4(8): 263–265p.
7. Lee SP, Sung IK, Kim JH, Lee SY, Park HS, Shim CS. Risk factors for the presence of symptoms in peptic ulcer disease. Clinical Endoscopy. 2017; 50(6): 578–584p.
8. Weng A, Su X, Yang C, Zheng B, Zheng L, Jian C, Fang J. Telephone follow-up by clinical pharmacists can improve treatment outcomes in patients with peptic ulcers: a prospective randomized study. Medicine. 2022; 101: 42p.
9. Feliciano O, Gutierrez O, Valdés L, Fragoso T, Calderin AM, Valdes AE, Llanes R. Prevalence of Helicobacter pylori vacA, cagA, and iceA genotypes in Cuban patients with upper gastrointestinal diseases. BioMed Research International. 2015; 2015: 753710.
10. Aro P, Storskrubb T, Ronkainen J, Bolling-Sternevald E, Engstrand L, Vieth M, Stolte M, Talley NJ, Agréus L. Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. American Journal of Epidemiology. 2006; 163(11): 1025–1034p.
11. Saeed M, Bass S, Chaisson NF. Which ICU patients need stress ulcer prophylaxis? Cleveland Clinic Journal of Medicine. 2022; 89(7): 363–367p.
12. Xia B, Xia HH, Ma CW, Wong KW, Fung FM, Hui CK, Chan CK, Chan AO, Lai KC, Yuen MF, Wong BC. Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated dyspeptic patients in Hong Kong. Alimentary Pharmacology & Therapeutics. 2005; 22(3): 243–249p.
13. Holle GE. Pathophysiology and modern treatment of ulcer disease. International Journal of Molecular Medicine. 2010; 25(4): 483–491p.
14. Tarris G, de Rougemont A, Charkaoui M, Michiels C, Martin L, Belliot G. Enteric viruses and inflammatory bowel disease. Viruses. 2021; 13(1): 104p.

15. Jeon HJ, Lee JS, Lee BS, Kim SH, Lee ES, Sung JK, Moon HS, Kang SH, Lee HS, Choi S, Sa-Kong H. Typhoid fever presenting with gastric ulcer bleeding. BMC Gastroenterology. 2022; 22(1): 116p.
16. Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol. 2011; 62(6): 591–599p.
17. Sonnenberg A. Historic changes of Helicobacter pylori-associated diseases. Alimentary Pharmacology & Therapeutics. 2013; 38(4): 329–342p.
18. Kavitt RT, Lipowska AM, Anyane-Yeboa A, Gralnek IM. Diagnosis and treatment of peptic ulcer disease. The American Journal of Medicine. 2019; 132(4): 447–456p.
19. Cover TL, Blaser MJ. *Helicobacter pylori* in health and disease. Gastroenterology. 2009; 136(6): 1863–1873p.
20. Gurusamy KS, Pallari E. Medical versus surgical treatment for refractory or recurrent peptic ulcer. Cochrane Database of Systematic Reviews. 2016; 2016(3): CD011523.
21. Kim BW. Diagnosis and treatment of peptic ulcer disease: present and future perspective. The Korean Journal of Gastroenterology. 2016; 67(6): 318–320p.
22. Savarino V, Marabotto E, Zentilin P, Savarino E. The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication. Expert Review of Clinical Pharmacology. 2019; 12(11): 1011–1012p.
23. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology. 2004; 127(2): 395–402p.
24. Chen Y, Liu Q, Hu F, Ma J. Identifying the best regimen for primary eradication of Helicobacter pylori: analysis of 240 cases. MicrobiologyOpen. 2020; 9(11): e1120.
25. Vrettos I, Voukelatou P, Katsoras A, Theotoka D, Kalliakmanis A. Diseases linked to polypharmacy in elderly patients. Current Gerontology and Geriatrics Research. 2017; 2017: 4276047.
26. Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 NIH patients and comparison with 2229 cases from the literature. Medicine. 2006; 85(6): 295p.
27. Osumi H, Fujisaki J, Suganuma T, Horiuchi Y, Omae M, Yoshio T, et al. A significant increase in the pepsinogen I/II ratio is a reliable biomarker for successful Helicobacter pylori eradication. PloS One. 2017; 12(8): e0183980.
28. Rockey DC, Koch J, Cello JP, Sanders LL, McQuaid K. Relative Frequency of Upper Gastrointestinal and Colonic Lesions in Patients with Positive Fecal Occult-Blood Tests. N Engl J Med. 1998; 339(3): 153–159p.
29. Laine L, Jensen DM. Management of patients with ulcer bleeding. Official Journal of the American College of Gastroenterology. 2012; 107(3): 345–360p.
30. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ. 2004; 329(7464): 480p.
31. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. The Journal of Clinical Investigation. 2003; 111(12): 1805–1812p.
32. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Journal of Haematology. 2009; 145(1): 24-33p.
33. Lanas A, Chan FK. Peptic ulcer disease. The Lancet. 2017; 390(10094): 613–624p.

34. Tarris G, de Rougemont A, Charkaoui M, Michiels C, Martin L, Belliot G. Enteric viruses and inflammatory bowel disease. Viruses. 2021; 13(1): 104p.
35. Joo MK, Park CH, Kim JS, Park JM, Ahn JY, Lee BE, et al. Clinical guidelines for drug-related peptic ulcer. Gut and Liver. 2020; 14(6): 707p.
36. Feliciano O, Gutierrez O, Valdés L, Fragoso T, Calderin AM, Valdes AE, et al. Prevalence of *Helicobacter pylori* vacA, cagA, and iceA genotypes in Cuban patients with upper gastrointestinal diseases. BioMed Research International. 2015; 2015: 753710.
37. Lee DP, Chang KJ. Endoscopic management of GERD. Digestive diseases and sciences. 2022; 67(5): 1455–1468p.

